Mumbai, May 22 -- After posting double-digit revenue growth in FY26, Sun Pharmaceutical Industries-India's biggest pharmaceutical company by revenue and market capitalization-has projected high single-digit growth for the current fiscal year (FY27), citing regulatory and macroeconomic challenges.

"We expect high single-digit consolidated top-line growth for FY27, based on our current understanding of the regulatory and macro environment," executive chairman Dilip Shanghvi told analysts in a post-earnings call on Friday, after the company announced its results for the fourth quarter and full year FY26.

The Mumbai-headquartered company's consolidated revenue grew 11.9% to Rs.58,220 crore, even as consolidated net profit rose 5% y-o-y to R...